Organic Active Ingredients TRIZ Cases

Pre-treatment autoimmune and liver biomarker screening identifies subjects likely to benefit from lanifibranor and helps limit adverse side-effect risk.

TROP2-targeted ADCs paired with decitabine or azacitidine enhance antitumor effects in resistant cancers and reduce dose-dependent toxicity.

Divinyl sulfone modifies and crosslinks hyaluronic acid derivatives to support biocompatibility and controlled physiological interaction.

Fibrin hydrogels support a flat, wrinkle-free RPE monolayer during surgery, then degrade to limit chronic inflammation and fibrosis.

Reduced nNOS signaling in hypothalamic circuits is addressed with NO agents that restore normal sexual behavior in PCOS-like mice.

Miotic aceclidine drops constrict the pupil to improve near and distance vision, potentially reducing reliance on lenses or surgery.

These isoindolinone and piperidine derivatives target IKZF2 degradation to focus immune activity at tumor sites and limit systemic toxicity.

Severe alcohol-associated hepatitis and ACLF need options beyond corticosteroids; Compound 1 activates FXR to regulate bile acid metabolism and protect the liver.

Targeting ligands on ZIF cages direct encapsulated agents toward prostate cancer cells while limiting exposure of essential organs.

Learn how dazucorilant modulates glucocorticoid receptors to slow ALS progression and improve overall survival.

Evaporating alcohol and water create a cooling sensation in a GTN-free formulation, supporting endogenous nitric oxide production without synthetic ED actives.

After antibiotic disruption, Clostridium scindens converts primary bile acids into secondary bile acids that inhibit C. difficile growth and toxin production.

Low cellular uptake and blood instability constrain mRNA vectors; unsaturated amino acid-based cationic lipids improve membrane fusion and cellular entry.

Lumateperone targets 5-HT2A and D2 pathways to treat encephalitis-related psychiatric symptoms and reinforce the blood-brain barrier.

A cyclical azabicyclic regimen treats malignant tumors while withdrawal periods limit retinal accumulation linked to ocular toxicity.

High intracellular ATP and kinome off-targets challenge PLK inhibition; PBD-binding small molecules target PLK1 selectively.

P2RY2 modulators alter B7-H3 activity to increase T cell anti-cancer function where CTLA-4 or PD-1/PD-L1 blockade has limited response.

Combining tenofovir alafenamide and emtricitabine in a low-excipient tablet preserves stability and bioequivalence while reducing dosage burden.

This case uses a piperidinyl bipyridyl compound to reduce seizure frequency and plasma 24HC levels in epileptic encephalopathies.

Low solubility, pH-dependent gelling, and light sensitivity are addressed with binder-based spray granulation for better dissolution and absorption.

Current HCM therapies often ease symptoms without addressing sarcomere dysfunction; these compounds inhibit beta cardiac myosin to improve relaxation.

Small-molecule GLP-1R agonists address injection dependence by supporting oral bioavailability while regulating glucose and reducing food intake.

TREM2 agonists compensate for ABCD1 dysfunction by preserving microglial activity and limiting astrocytosis in X-ALD.

See how optimized AAK1 inhibitor synthesis controls impurities and harmful byproducts for safer, higher-yield scale-up.

A diminazene-derived library uses fluorescence displacement and calorimetry to identify molecules that stabilize or destabilize MALAT1 triple helices.

Peptide GLP-1 agonists improve blood glucose control but have poor oral bioavailability; fused imidazole derivatives offer an oral small-molecule approach.

Substituted oxopyridine derivatives target factor XIa to improve pharmacokinetic behavior, extend half-life, and reduce bleeding risk.

P2Y12 receptor modulation by clopidogrel and related agents targets perisynaptic Schwann cells to preserve and repair NMJs.

A single high dose of budiodarone targets sustained plasma levels to cardiovert AFib to sinus rhythm within 90 minutes.

Low water solubility limits oral efinaconazole bioavailability; a polyethylene glycol co-crystal improves dissolution and stability.

Heteroaryl compounds inhibit xanthine oxidase to lower serum uric acid, addressing toxicity and limited efficacy in existing gout treatments.

Selective dimethoxyphenylalkylamine compounds target 5-HT2A signaling and recruit β-arrestin 2 to pursue therapy with fewer hallucinogenic effects.

Limited knockdown duration and oligonucleotide stability are addressed with modified RNAi sequences that reduce LDHA activity in hepatocytes.

Measuring alpha defensin in CSF, with a cutoff above about 250 mg/L, supports EVD-associated ventriculitis diagnosis and targeted antibiotic use.

Remote acyl participation and SN2 substitution build stereospecific O5 bonds despite poor rare-sugar reactivity, enabling antigen screening.

Sequential solvent fractionation and resin chromatography isolate new dimers from I. trichantha tubers for antitumor research.

Stirring elacestrant dihydrochloride in chloroform and drying produces Form CSII with higher solubility, flowability, and stability.

Novel metal-binding compounds address inadequate conventional inhibitors by regulating metalloenzymes linked to cancer, Alzheimer's disease, and hemochromatosis.

Current treatments mainly manage symptoms; fused amino pyrimidine compounds modulate KCC2 to regulate chloride levels and neuronal inhibition.

Local delivery of an anti-SEMA4D blocking antibody limits immune cell infiltration in salivary glands while reducing systemic side effects.

A stabilized topical composition uses specific bases and excipients to keep bis-(2-chloroethyl)methylamine at 90% or more for up to 90 days.

Acid-resistant delayed release limits stomach exposure, helping preserve active (Z)-endoxifen and deliver it in the intestine.

Defined salts and solid forms, including hydrates and solvates, address variable pharmaceutical stability and bioavailability in treatment.

CRISPR/Cas editing of PKM in CHO cells reduces lactate accumulation, helping preserve cell viability, productivity, and recombinant protein quality.

Learn how CircCYB knockdown promotes apoptosis in lung cancer cells while sparing normal cells for targeted treatment.

Small-molecule compounds inhibit APOL1 to address targeted treatment gaps in APOL1-associated nephropathies and renal allograft loss.

The free acid had insufficient high-dose bioavailability; crystalline cholinate improves solubility, handling, and storage stability.

Retigabine’s efficacy and tolerability trade-off is addressed with Kv7.2/7.3 potentiators that normalize motor neuron excitability.

Specific X-ray diffraction peaks identify a monoclinic compound B crystal form that improves stability and pharmacokinetics for selective FGFR4 inhibition.

EED-binding compounds address weak PRC2 inhibitor activity against EZH2 activating mutations while improving cellular potency, stability, and safety.

Novel tetracyclic xanthene derivatives target the HCV NS5A protein to block viral replication cycles.

Mavrilimumab targets the GM-CSFRalpha receptor to reduce disease activity scores and improve physical function in rheumatoid arthritis patients.

Topical polyurea-urethane polymer forms a protective film on the nail surface, resolving slow treatment times while improving nail strength and color.

Low sodium dextrose infusate creates a steep concentration gradient to extract excess fluid and sodium, resolving dialysis disequilibrium syndrome risks.

Crystalline Form N of Afatinib monomaleate improves compressibility and reduces hygroscopicity by modifying particle morphology during solvent crystallization.

Mucoadhesive polymer coatings enable urea derivative nanoparticles to bypass mucus trapping, delivering active ingredients directly to affected ocular tissues.

Quaternary ammonium salt derivatives of phenanthroindolizidine alkaloids utilize nitroimidazole moieties to achieve selective cytotoxicity in hypoxic tumor environments.

Replaces oil carriers with fatty acids to resolve low bioavailability and high variability.

General Formula I, II, and III compounds activate IGF1 signaling to ameliorate fatty liver while simplifying synthesis compared to complex natural products.

A rasagiline mouth-dissolving composition uses water-swellable polymers to enable rapid oral absorption.

Albumin nanoformulation encapsulates APG-1252, reducing platelet toxicity while maintaining circulation stability.

Using c-MAF gene expression to select patients for zoledronic acid therapy prevents unnecessary treatments and reduces harm from ineffective therapies.

Fused tricyclic urea compounds inhibit Raf kinase dimers, overcoming resistance in RAS mutant tumors that evade first-generation inhibitors.

Small molecule inhibitor targets SPINK2 protein in leukemic stem cells to induce cell death and inhibit proliferation.

Modifying quinoline derivatives improves metabolic stability and reduces toxicity in BK B2 receptor antagonists.

Fused tetracycle derivatives inhibit hepatitis C virus replication by targeting the NS5A protein.

Cacao polyphenol composition elevates sympathetic nerve activity in brown adipose tissue and adrenal glands without theobromine or caffeine adverse effects.

Substituted tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives act as S1P1 receptor agonists to modulate leukocyte trafficking and sequester lymphocytes.

Estetrol crosses the blood-brain barrier to treat diffuse white matter injury, avoiding invasive delivery methods required for larger therapeutic agents.

A 104-gene DHIT signature classifies aggressive B-cell lymphomas into distinct molecular subgroups.

Continuous drop-on-demand printing enables personalized microdose production while resolving batch processing contradictions in cost and adaptability.

Peptidomimetic compounds disrupt the YAP1-Oct4 molecular interaction to suppress lung cancer stem cell self-renewal and viability.

Synthetic formulas integrate human milk oligosaccharides with antioxidants to reduce cytokine production and oxidative stress in preterm infants.

Ubrogepant antagonizes CGRP receptors to relieve migraine pain without cardiovascular risks associated with triptans.

Mesenchymal stem cell exosomes deliver therapeutic RNA to inhibit hepatic stellate cells and reduce collagen deposition.

Methanol solubilization and water precipitation purify quinolinyl derivatives, resolving industrial scale compliance issues.

4H-pyran-4-one derivatives inhibit CYP11A1 to block upstream steroid synthesis and overcome resistance in castration-resistant prostate cancer.

Intratumoral administration of L-2,4-diaminobutyric acid and prazosin reduces toxicity to normal tissues while inhibiting tumor growth.

Wet granulating apixaban with large particles reduces production costs while maintaining fast dissolution rates through optimized binder systems.

Combining tramadol with ophthalmic lubricants reduces dry eye pain while enhancing drug absorption.

Triple alkyl chains form lipophilic cores that improve cellular uptake and drug loading while reducing toxicity associated with conventional delivery systems.

A defined crystal form of a hepatitis B surface antigen inhibitor reduces viral load through specific chiral configurations.

Chiral diaryl macrocycles overcome kinase resistance by simultaneously targeting MET, ALK, ROS1, AXL, TRKs, and JAKs.

Morpholine-substituted quinolin-4-one derivatives enhance selective binding to disease-relevant PI3K isoforms while minimizing off-target cytotoxic effects.

Fungal fermentation yields water-soluble melanin to attenuate X-rays and gamma rays while lowering production costs.

MicroRNA combinations and NFκB activators reprogram precursor cells into functional cardiomyocytes, addressing limited heart self-renewal capacity.

Hydrotropes mediate the dissolution of hydrophobic phenolic compounds and adenosine analogues in water, resolving low solubility without organic solvents.

Gel capsule formulation creates high-viscosity barrier upon water contact, preventing parenteral injection while maintaining oral bioavailability.

Substituted heterocyclic compounds inhibit lysine specific demethylase-1 to regulate gene transcription and treat cancer progression.

Form XIV ethanol solvate delivers stable crystalline structure with defined X-ray diffraction peaks, resolving pharmaceutical stability challenges.

C-2 substitution of fulvestrant enhances oral bioavailability and brain penetration while reducing metabolic sites for lower toxicity.

Imidazothiadiazole compounds inhibit protease-activated receptor 4 to block platelet aggregation.

Lipophilic anti-inflammatory agents embedded in lipid nanoparticles suppress immune activation during drug delivery.

Segmenting synthesis into distinct catalytic and hydrogenation stages maintains manufacturing precision while scaling production beyond one kilogram.

Alkyne substituted quinazoline derivatives stabilize the inactive kinase conformation of oncogenic EGFR variants.

Enzymatic degradation of fibrotic cords via collagenase reduces recovery time while maintaining treatment effectiveness.

An organosol polymeric coat prevents dose dumping and burst effects by combining water-soluble gel-forming polymers with insoluble organosoluble polymers.

Modulating NR2F6 targets leukemia stem cells to improve therapy effectiveness while reducing toxicity from non-specific cytotoxic effects.

Engineered Firmicutes microbes express cholesterol oxidoreductase to convert intestinal cholesterol into coprostanol, bypassing complex gut microbiota analysis.

Sequential additive addition reduces surface tackiness while maintaining storage stability and preventing brittleness.

Treprostinil exposure primes mesenchymal stem cells to reduce pro-inflammatory cytokines and treat pulmonary arterial hypertension.

A hyaluronic acid and liposome composition delivers Allantoin and Acetyl-Carnitine to skin tissue.

Small molecule somatostatin modulators overcome peptide resistance and enable oral delivery.

New N-[(1H-pyrazol-1-yl)aryl]-1H-indole compounds provide reversible P2Y12 antagonism, resolving irreversible inhibition risks in cardiovascular therapy.

9H-pyrrolo-dipyridine derivatives bind selectively to Tau aggregates with high affinity.

DI17E6 antibody blocks latent TGF-β activation via alpha-v integrin targeting, resolving the unmet need for effective fibrosis therapies.

Optimized pH and composite excipients stabilize tranexamic acid in aqueous oral rinses, preventing discoloration during shelf storage.

Replacing propylene glycol with fatty acid esters and co-solvents maintains chemical stability while reducing skin irritation.

D-glucose, fiber, and protein additives modify sweet low-digestible carbohydrate formulations to improve gastrointestinal tolerance.

Cyclic peptides achieve high MCR-1 selectivity to reduce pro-inflammatory cytokines while minimizing toxicity.

Benzothiophene-substituted cyclohexanes achieve high D3/D2 selectivity, reducing extrapyramidal side effects in schizophrenia treatment.

Heterocyclic compounds selectively inhibit mutant PI3Kα kinase activity, reducing hyperglycemia and hyperinsulinemia caused by wild-type inhibition.

A ready-to-infuse aqueous vinca alkaloid solution in a flexible container maintains stability at room temperature.

Parenteral administration bypasses saturable intestinal transport to resolve dose-dependent bioavailability inconsistencies.

Bicyclo arylalkyl pyrazole compounds block tryptophan degradation to reverse immunosuppression and enhance T-cell activation against tumors.

Essential amino acid infusion suppresses protein catabolism and controls serum phosphate levels in dialysis patients.

A pharmaceutical composition containing a FABP4 inhibitor reduces lipid synthesis in sebocytes to lower sebum secretion.

Ultrasonic heating accelerates the synthesis of a bipyridine antioxidant, reducing reaction time and waste compared to conventional thermal methods.

Endogenous polyamines crosslink hyaluronic acid at low modification degrees, resolving mechanical stress and cohesiveness trade-offs.

Ligand-conjugated siRNA compositions inhibit angiotensinogen expression, alleviating hypertension without multi-drug side effects.

Aqueous gel vehicle disperses oily polyunsaturated fatty acids using hydrophilic polymers.

A 1,8-cineole pharmaceutical composition inhibits the Wnt/β-catenin signaling pathway to reduce tumor cell proliferation.

Inhaled pirfenidone formulations bypass the gastrointestinal tract to increase lung tissue concentration while reducing adverse events.

Total synthesis of ixabepilone utilizes crystalline Epothilone B intermediates, overcoming fermentation complexity and low yields.

Zinc oxide absorbs moisture while copper sulfate targets pathogens, resolving the trade-off between antimicrobial reliability and formulation complexity.

Recrystallization and acid catalysis lower genotoxic 4-MMPPO below 10 ppm in tolperisone formulations.

A gene editing system uses dual nicking proteins to introduce precise modifications without double-strand breaks.

Density matching via thickening agents prevents microsphere aggregation while hypotonic solutions accelerate wound healing.

EDTA and citrate chelate essential metals to inhibit growth, avoiding sodium hypochlorite safety risks.

Replacing multi-solvent workflows with a unified ester medium eliminates tedious column purification, reducing reaction time and boosting yield.

Branching cores and reversible linkers achieve high drug loading while maintaining water solubility, reducing interpatient variability.

An additive with hydrophilic and drug-affinity parts enables uniform drug release from medical device coatings, reducing restenosis risks.

Pyridazinone-based compounds overcome resistance and improve treatment outcomes across diverse influenza strains.

Compound A treats narcolepsy by activating orexin-2 receptors, addressing symptom coverage gaps in current therapies.

Phosphoramidic acid prodrugs convert to active inhibitors via hydrolysis, maintaining stable solubility across varying gastric pH conditions.

Spray dried lipid excipient powder creates unified multi-drug motifs that extend plasma drug concentrations for HIV treatment.

Benzimidazole-carbohydrate conjugates enter cancer cells via GLUT channels, inhibiting microtubule formation while minimizing toxicity to normal cells.

Novel solid forms of Compound I achieve low residual solvent levels through controlled precipitation and spray drying processes.

Hydrophobic conjugation eliminates unstable synthetic linkers, resolving linker instability and healthy tissue toxicity in cancer therapeutics.

Liposome bilayers encapsulate hydrophobic salicylic acid derivatives, resolving solvent incompatibility and enhancing skin permeation.

A pharmaceutical composition containing a PKR inhibitor reduces inflammatory cell counts in bronchoalveolar lavage fluid.